Literature DB >> 455895

Techniques for plasma protein binding of demethylchlorimipramine.

L Bertilsson, R Braithwaite, G Tybring, M Garle, O Borgå.   

Abstract

The cerebrospinal fluid (CSF) and plasma levels of demethylchlorimipramine (DMCI) were determined during treatment of depression or obsessive-compulsive disorders with chlorimipramine. In 18 patients the mean CSF/plasma ratio of DMCI was 2.6% +/- 0.7 SD with fourfold variation (1.1% to 4.0%). In spite of this variation, the levels in CSF and plasma at steady state correlated closely (r = 0.91; p less than 0.001). With equilibrium dialysis for the determination of the protein binding of DMCI, a much higher free fraction was found in patients (8.0 +/- 1.6%) and in control subjects (8.2 +/- 1.4%). It was shown that part of the plasma binding capacity was lost during the incubation. Results obtained by ultrafiltration (3.9 +/- 1.0% unbound drug) were closer to the in vivo results, but this method also had disadvantages; much of the drug was absorbed on the ultrafiltration dialysis membrane. Our results suggest that there is a need for care in the selection of a technique for studies of drug protein binding.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455895     DOI: 10.1002/cpt1979262265

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein.

Authors:  D Tinguely; P Baumann; M Conti; M Jonzier-Perey; J Schöpf
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 4.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

6.  Plasma protein binding of perazine and amitriptyline in psychiatric patients.

Authors:  M Brinkschulte; H J Gaertner; H W Schied; U Breyer-Pfaff
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Plasma protein binding of etidocaine during pregnancy and labour.

Authors:  D J Morgan; B B Koay; J D Paull
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Modulation of nonspecific binding in ultrafiltration protein binding studies.

Authors:  Kyoung-Jin Lee; Rachel Mower; Tom Hollenbeck; Jesus Castelo; Nikole Johnson; Perry Gordon; Patrick J Sinko; Kevin Holme; Yong-Hee Lee
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

Review 9.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

10.  Binding of amitriptyline and nortriptyline in plasma determined from their equilibrium distributions between red cells and plasma, and between red cells and buffer solution.

Authors:  J E Burch; S G Roberts; M A Raddats
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.